CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires

El Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC) es una Asociación civil sin fines de lucro, entidad de bien público y universitaria. Nació en 1958 a partir de la visión innovadora del Dr. Norberto Quirno y de un grupo de discípulos comprometidos, que quisieron mejorar la medicina argentina. Esta visión ha convertido a esta institución en líder y referente en el área de la salud.
logoCEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Av. Galvan 4102, CABA, Buenos Aires
Select an option

Specializations

Esclerosis múltiple
Covid-19
Coronavirus
Cáncer
Enfermedad de Crohn
Influenza A
Linfoma
Lupus eritematoso sistémico
Lupus eritematoso sistémico
Melanoma
Pan Tumor
Poliquistosis renal autosómica dominante

Our team

Medical staff
Juan Ignacio Rojas
Stella Zarza
Nicolás Torresi
Pablo Bonvehí
Vanina Wainsztein
Nicolás Torressi
Alejandro Kuzminin
Aldo Perfetti
Diego Castro
Corina Capparelli
Victoria Marroquin
Florencia Perazzo
Gonzalo Recondo
Analia Patricia Alvarez
Máximo De la Vega
Pablo Olivera Sendra
Fernando Galanternik
Patricio José Duarte

Open studies

Lung cancer
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection - ADAURA2 - AstraZenecaSee more
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer - GlaxoSmithKlineSee more
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.See more
Leukemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Lymphoma
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) - CC-99282-NHL-001 - CelgeneSee more
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma - GOLSEEK-1 - CelgeneSee more
Alzheimer disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease - PROGRESS-AD - GlaxoSmithKlineSee more
Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy - IMvigor011 - Hoffmann-La RocheSee more
Breast Cancer
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Cardiovascular disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - ZEUS - Novo Nordisk A/SSee more
Colorectal cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - AmgenSee more
Covid-19
Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease - CARR-COV-02 - Centro de Educación Medica e Investigaciones Clínicas Norberto QuirnoSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Graft versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. - ROCKnrol-1 - SanofiSee more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Renal disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation - ZEUS - Novo Nordisk A/SSee more
Ulcerative colitis
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 - Abivax S.A.See more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy